ALNYLAM PHARMACEUTICALS, INC. (ALNY) Total liabilities 2016–2025
ALNYLAM PHARMACEUTICALS, INC. (ALNY) total liabilities at each fiscal year-end, per SEC filings.
$4.2BFY2025 · since FY2016: $342.6M → $4.2B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $4.2B | +0.1% |
| FY2024 | $4.2B | +3.0% |
| FY2023 | $4.1B | +9.3% |
| FY2022 | $3.7B | +21.3% |
| FY2021 | $3.1B | +27.8% |
| FY2020 | $2.4B | +150.0% |
| FY2019 | $956.4M | +250.6% |
| FY2018 | $272.8M | +19.5% |
| FY2017 | $228.3M | -33.4% |
| FY2016 | $342.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ALNY financial trends
ALNY RevenueALNY Net incomeALNY Net marginALNY Gross profitALNY Gross marginALNY Operating incomeALNY Operating marginALNY Operating cash flowALNY Free cash flowALNY Capital expendituresALNY Return on equityALNY Stock buybacksALNY Dividends paidALNY Total assetsALNY Shareholders’ equityALNY overview →